Skip to main content

Table 1 Baseline demographic and clinical characteristics of the patients

From: Effect of dexamethasone and ramosetron on the prevention of postoperative nausea and vomiting in low-risk patients: a randomized, double-blind, placebo-controlled, multicenter trial

Characteristic

Group C (n = 58)

Group R (n = 58 )

Group DR (n = 58)

P value

Age (years)

56.5 ± 10.0

59.2 ± 8.3

56.4 ± 11.7

0.247

Sex (female)

6 (10%)

7 (12%)

10 (17%)

0.521

Weight (kg)

71.0 ± 10.3

69.8 ± 11.3

69.9 ± 12.9

0.612

Height (cm)

166.9 ± 7.3

167.7 ± 6.1

167.3 ± 8.2

0.603

Nonsmoking status

26 (45%)

33 (57%)

35 (60%)

0.212

Apfel score, n, (%)

   

0.835

0

1

2

10 (17%)

25 (43%)

23 (40%)

14 (24%)

21 (36%)

23 (40%)

13 (22%)

20 (34%)

25 (43%)

 

Duration of surgery (min)

Duration of anesthesia (min)

ASA status I/II, n, (%)

85.3 ± 61.5

122.6 ± 67.0

30 (52%)/28 (48%)

73.0 ± 50.5

110.4 ± 62.1

30 (52%)/28 (48%)

61.9 ± 38.2

97.1 ± 48.6

39 (67%)/19 (33%)

0.691

0.713

0.150

Type of surgery

   

0.862

Orthopedic surgery

23 (40%)

29 (50%)

28 (48%)

 

Rhinologic surgery

16 (27%)

14 (24%)

17 (29%)

 

Urologic surgery

11 (19%)

10 (17%)

8 (14%)

 

Other

8 (14%)

5 (9%)

5 (9%)

 
  1. Data are presented as mean score ± SD or n (%) of patients. Data were analyzed using analysis of variance (continuous variables) or the χ2 test (incidence variables). Patients in Group C received 2 mL of intravenous 0.9% saline at the end of surgery; those in group R received 0.3 mg of intravenous ramosetron at the end of surgery; and those in group DR received 5 mg of intravenous dexamethasone at the induction of anesthesia and 0.3 mg of intravenous ramosetron at the end of surgery. The Apfel risk score consists of four predictors: nonsmoking, female sex, history of motion sickness and/or postoperative nausea and vomiting, and postoperative opioid usage. ASA: American Society of Anesthesiologists physical status